Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

NCT01419639 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01419639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01419639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
December 31, 2013
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type ii